The trademark application Kesimpta ofatumumab was filed by Novartis AG, a corporation established under the laws of the Swiss Confederation (the "Applicant"). The application was published for oppositions on February 24, 2021, and it was registered by office on June 3, 2021 without any oppositions.
The application was filed in English (French was selected as the second language).
Change of name and professional address of the trademark registration was recorded on June 8, 2023. Appointment and Replacement of representative of the trademark registration was recorded on May 2, 2024.